

# MARKET REPORT



## Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 or **Email:** [pdb@bioportfolio.co.uk](mailto:pdb@bioportfolio.co.uk)

# Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016

Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016

## Summary

GlobalData's clinical trial report, "Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016" provides an overview of Multiple Myeloma (Kahler Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Myeloma (Kahler Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

\*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

## Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

\*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

## Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

\*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

## Additional Details

**Publisher :** Global Data

**Reference :** GDHC3734CTIDB

**Number of Pages :** 1665

**Report Format :** PDF

**Publisher Information :**



**GlobalData** »

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

# Table Of Contents for Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016 [Published by Global Data]

- Table of Contents 2List of Tables 3List of Figures 4Report Guidance 5Clinical Trials by Region 6Clinical Trials and Average Enrollment by Country 7Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10Top Five Countries Contributing to Clinical Trials in Europe 11Top Countries Contributing to Clinical Trials in North America 12Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13Top Five Countries Contributing to Clinical Trials in Central and South America 14Clinical Trials by G7 Countries: Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials 15Clinical Trials by Phase in G7 Countries 16Clinical Trials in G7 Countries by Trial Status 17Clinical Trials by E7 Countries: Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials 18Clinical Trials by Phase in E7 Countries 19Clinical Trials in E7 Countries by Trial Status 20Clinical Trials by Phase 21In Progress Trials by Phase 22Clinical Trials by Trial Status 23Clinical Trials by End Point Status 24Subjects Recruited Over a Period of Time 25Clinical Trials by Sponsor Type 26Prominent Sponsors 27Top Companies Participating in Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials 28Prominent Drugs 30Latest Clinical Trials News on Multiple Myeloma (Kahler Disease) 31Sep 14, 2016: GlycoMimetics Doses First Patient in Phase 1 Clinical Trial of Drug Candidate GMI-1271 for Multiple Myeloma 31Sep 09, 2016: Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level 31Sep 06, 2016: Karyopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma 31Aug 30, 2016: Karyopharm to Host Conference Call with Update on Multiple Myeloma Plans 34Aug 25, 2016: Data from Phase III CASTOR Study of Daratumumab Published in The New England Journal of Medicine 34Aug 19, 2016: Additional two centers started screening of Multiple Myeloma patients in OV's APO010 Study 35Jul 25, 2016: Daratumumab (DARZALEX) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Use in Combination with Standard of Care Regimens for Patients with Multiple Myeloma 36Jul 13, 2016: Immunotherapy benefits relapsed stem cell transplant recipients 37Jul 07, 2016: Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 data for DARZALEX (daratumumab) and the Janssen Immuno-oncology Strategy and Portfolio 37Clinical Trial Profile Snapshots 38Appendix 1662Abbreviations 1662Definitions 1662Research Methodology 1663Secondary Research 1663About GlobalData 1664Contact Us 1664Disclaimer 1664Source 1665

# List Of Tables in Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016 [Published by Global Data]

## List of Tables

- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Region, 2016\* 6
- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016\* 8
- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016\* 9
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016\* 10
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016\* 11
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, North America, Top Countries, 2016\* 12
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016\* 13
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016\* 14
- Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, G7 Countries (%), 2016\* 15
- Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016\* 16
- Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016\* 17
- Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, E7 Countries (%), 2016\* 18
- Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016\* 19
- Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016\* 20
- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Phase, 2016\* 21
- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2016\* 22
- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2016\* 23
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2016\* 24
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
- Multiple Myeloma (Kahler Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016\* 26
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2016\* 27
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016\* 29
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016\* 30

# List Of Figures, Charts and Diagrams in Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016 [Published by Global Data]

## List of Figures

- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Region (%), 2016\* 6
- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016\* 7
- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016\* 9
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016\* 10
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016\* 11
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2016\* 12
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016\* 13
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016\* 14
- Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, G7 Countries (%), 2016\* 15
- Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016\* 16
- Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016\* 17
- Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, E7 Countries (%), 2016\* 18
- Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016\* 19
- Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016\* 20
- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2016\* 21
- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016\* 22
- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2016\* 23
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2016\* 24
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
- Multiple Myeloma (Kahler Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016\* 26
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2016\* 27
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016\* 28
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016\* 30





# How to Buy...

Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016 [Published by Global Data]

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/27418>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [pdb@bioportfolio.co.uk](mailto:pdb@bioportfolio.co.uk) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$2500** | Single User Price
- \$5000** | Site License Price
- \$7500** | Enterprise License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.